Graefen M - Search Results

1

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. Tosco L, et al. Among authors: graefen m. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):407-412. doi: 10.1038/pcan.2017.29. Epub 2017 May 9. Prostate Cancer Prostatic Dis. 2017. PMID: 28485390

2

Surgical therapy for localized prostatic carcinoma.

Noldus J, Hammerer P, Graefen M, Huland H. Noldus J, et al. Among authors: graefen m. J Cancer Res Clin Oncol. 1997;123(3):180-4. doi: 10.1007/BF01214671. J Cancer Res Clin Oncol. 1997. PMID: 9119884

3

The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.

Noldus J, Graefen M, Huland E, Busch C, Hammerer P, Huland H. Noldus J, et al. Among authors: graefen m. J Urol. 1998 Jun;159(6):2004-7; discussion 2007-8. doi: 10.1016/S0022-5347(01)63227-0. J Urol. 1998. PMID: 9598507

4

Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.

Henke RP, Hammerer P, Graefen M, Erbersdobler A, Neumann M, Berger J, Huland H. Henke RP, et al. Among authors: graefen m. Cancer. 1998 Sep 1;83(5):977-88. Cancer. 1998. PMID: 9731903

5

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Haese A, et al. Among authors: graefen m. J Urol. 1999 Apr;161(4):1206-11. J Urol. 1999. PMID: 10081870 Clinical Trial.

6

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H. Graefen M, et al. Eur Urol. 1999;36(1):21-30. doi: 10.1159/000019922. Eur Urol. 1999. PMID: 10364651

7

[Prognostic markers for prostate cancer].

Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H. Graefen M, et al. Urologe A. 2000 Jan;39(1):14-21. doi: 10.1007/s001200050004. Urologe A. 2000. PMID: 10663191 Review. German.

8

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.

Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H. Graefen M, et al. J Urol. 2001 Mar;165(3):857-63. J Urol. 2001. PMID: 11176486

9

Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.

Hammerer P, Graefen M, Henke RP, Haese A, Palisaar J, Huland E, Huland H. Hammerer P, et al. Among authors: graefen m. Anticancer Res. 2000 Nov-Dec;20(6D):5253-5. Anticancer Res. 2000. PMID: 11326705

10

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H. Haese A, et al. Among authors: graefen m. Prostate. 2001 Oct 1;49(2):101-9. doi: 10.1002/pros.1123. Prostate. 2001. PMID: 11582588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

927 results

Search Page